Peluang Terapi Metformin Selain Sebagai Obat Diabetes DOI Aktif
Kategori
Kedokteran dan Kesehatan
Penerbit
UmriPress
ISBN
978-634-04-3616-7
Halaman
68 hal
E-ISBN
978-634-04-2610-6 (PDF)
Terbit
10 Aug 2025
Dimensi
155 × 230 mm
Stok
10
Format tersedia
Hardcopy E-Book

KATA KUNCI

Metformin, diabetes tipe 2, terapi alternatif, anti kanker, anti-inflamasi, PCOS

Hardcopy -10%
Rp 54.000

Rp 60.000

E-Book -10%
Rp 27.000

Rp 30.000

Pesan via WhatsApp

Metformin dikenal luas sebagai terapi utama untuk diabetes tipe 2. Namun, penelitian terbaru menunjukkan bahwa metformin juga memiliki potensi terapeutik yang menjanjikan di luar itu, seperti sebagai agen anti kanker, anti-inflamasi, serta dalam penanganan sindrom ovarium polikistik (PCOS).

Buku ini hadir untuk menggali peluang-peluang baru dari metformin, memberikan wawasan ilmiah dan klinis yang dapat dimanfaatkan oleh peneliti, tenaga medis, maupun apoteker. Semoga buku ini menjadi kontribusi positif bagi pengembangan terapi berbasis metformin di masa depan.


Kata Pengantar.....................................................................................Iv

Daftar Isi................................................................................................v

Bab. 1 pendahuluan...............................................................................1

1.1 Sejarah dan Perkembangan......................................................2

1.2 Mekanisme Kerja.....................................................................3

Bab. 2 Farmakokinetik dan Farmakodinamik Metformin.....................4

2.1. Absorpsi, Distribusi, Metabolisme, dan Ekskresi...................4

2.2. Mekanisme Kerja dan Efek Farmakologi...............................6

Bab. 3 Metformin dan Kesehatan Kardiovaskular..............................12

Bab. 4 Metformin Sebagai Anti Inflamasi..........................................17

4.1 Metformin sebagai anti inflamasi..........................................17

4.2 Mekanisme Aksi Metformin dalam Proses Anti-Inflamasi...17

4.3 Bukti Klinis dan Preklinis Efek Anti-Inflamasi Metformin. .18

4.4 Potensi Klinis Metformin sebagai Agen Terapi Anti-Inflamasi

.....................................................................................................19

Bab. 5 metformin sebagai anti kanker.................................................20

5.1 Metformin Sebagai Anti Kanker............................................20

5.2 Mekanisme Aksi Metformin dalam Penghambatan Sel Kanker

.....................................................................................................20

5.3 Bukti Klinis dan Preklinis Penggunaan Metformin dalam

Terapi Kanker..............................................................................21

5.4 Penggunaan Metformin sebagai Adjuvan dalam Terapi

Kanker..........................................................................................22


vi


5.5 Tantangan dan Potensi Masa Depan Metformin dalam

Onkologi......................................................................................22

Bab. 6 Metformin dan Gangguan Metabolik Non-Diabetes...............24

6.1 Metformin dalam Terapi Sindrom Polikistik Ovarium (PCOS)

.....................................................................................................24

6.2 Metformin dan Penyakit Hati Berlemak Non-Alkohol

(NAFLD).....................................................................................27

6.3. Metformin dalam Manajemen Obesitas................................31

Bab. 7 Metformin dan Anti Penuaan...................................................34

7.1 Metformin sebagai Obat Anti-Penuaan.................................34

7.2 Efek Metformin terhadap Peradangan dan Stres Oksidatif...36

7.3 Studi Klinis Metformin dan Umur Panjang...........................38

Bab. 8 efek metformin pada neuerologi..............................................41

8.1 Manfaat Metformin Terkait Penyakit Alzheimer Dan Penyakit

Neurodegeneratif.........................................................................42

8.2 Efek Metormin Terhadap Parkinson......................................43

8.3. Metormin Terhadap Kesehatan Otak....................................44

Daftar Pustaka.....................................................................................48

Adone, A., Fulmali, D.G., 2023. Polycystic Ovarian Syndrome in Adolescents. Cureus 15, e34183. https://doi.org/10.7759/cureus.34183
Agrawal, A., Dave, A., Jaiswal, A., 2023. Type 2 Diabetes Mellitus in Patients With Polycystic Ovary Syndrome. Cureus 15, e46859. https://doi.org/10.7759/cureus.46859
Akhtar, D.H., Iqbal, U., Vazquez-Montesino, L.M., Dennis, B.B., Ahmed, A., 2019. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 7, 362–370. https://doi.org/10.14218/JCTH.2019.00028
Ala, Moein, Ala, Mahan, 2021. Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next? ACS Pharmacol Transl Sci 4, 1747–1770. https://doi.org/10.1021/acsptsci.1c00167
Allow, S., Sarhat, E., 2023. METFORMIN EFFECTS ON BLOOD LEVELS OF GREMLIN-1 IN POLYCYSTIC OVARIAN WOMEN. Georgian Med News 51–55.
Attia, G.M., Almouteri, M.M., Alnakhli, F.T., 2023. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. Cureus 15, e44493. https://doi.org/10.7759/cureus.44493
Augustine, S., Harshitha, R., Sangayya Hiremath, R., Anil Kumar, H., Prajwal, K.C., 2023. Non-alcoholic Fatty Liver Disease in Overt Hypothyroidism: A Cross-Sectional Study in a Tertiary Care Hospital. Cureus 15, e37094. https://doi.org/10.7759/cureus.37094
Ayaz, A., Alwan, Y., Farooq, M.U., 2013. Metformin-clomiphene citrate vs. clomiphene citrate alone: Polycystic ovarian syndrome. J Hum Reprod Sci 6, 15–18.
Azizah, N., Ghifari, A.A., Adikusuma, W., Hamidy, M.Y., others, 2024. Exploring the diverse therapeutic benefits of metformin: from anti-cancer to anti-inflammation and PCOS management. Journal of Applied Pharmaceutical Research 12, 1–10.
Bai, B., Chen, H., 2021. Metformin: A Novel Weapon Against Inflammation. Front Pharmacol.
Brunton, L.L., Knollmann, B.C., Hilal-Dandan, R., others, 2018. Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw Hill Medical New York.
Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF, Yang X. Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK-dependent mechanisms. J Cell Mol Med 2022;26:4886–903. https://doi.org/10.1111/jcmm.17519.
Budd, J., Cusi, K., 2020. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Curr Diab Rep 20, 59. https://doi.org/10.1007/s11892-020-01349-1
Cedillo, L., Ahsan, F.M., Li, S., Stuhr, N.L., Zhou, Y., Zhang, Y., Adedoja, A., Murphy, L.M., Yerevanian, A., Emans, S., Dao, K., Li, Z., Peterson, N.D., Watrous, J., Jain, M., Das, S., Pukkila-Worley, R., Curran, S.P., Soukas, A.A., 2023. Ether lipid biosynthesis promotes lifespan extension and enables diverse pro-longevity paradigms in Caenorhabditis elegans. Elife 12, e82210. https://doi.org/10.7554/eLife.82210
Chang JE, Choi MS. A molecular perspective on the potential benefits of metformin for the treatment of inflammatory skin disorders. Int J Mol Sci 2020;21:1–13. https://doi.org/10.3390/ijms21238960.
Costello, M., Garad, R., Hart, R., Homer, H., Johnson, L., Jordan, C., Mocanu, E., Qiao, J., Rombauts, L., Teede, H.J., Vanky, E., Venetis, C., Ledger, W., 2019. A Review of First Line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome. Med Sci (Basel) 7, 95. https://doi.org/10.3390/medsci7090095
Curry, S.H., Whelpton, R., 2017. Introduction to drug disposition and pharmacokinetics. John Wiley & Sons.
Dai, D.-F., Kang, P., Bai, H., 2023. The mTOR signaling pathway in cardiac aging. J Cardiovasc Aging 3, 24. https://doi.org/10.20517/jca.2023.10
Dehkordi, A.H., Abbaszadeh, A., Mir, S., Hasanvand, A., 2019. Metformin and its anti-inflammatory and anti-oxidative effects; new concepts. J Renal Inj Prev 8, 54–61.
Demaré S, Kothari A, Calcutt NA, Fernyhough P. Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system. Expert Rev Neurother 2021;21:45–63. https://doi.org/10.1080/14737175.2021.1847645.
Ertunç, D., Tok, E.C., Aktaş, A., Erdal, E.M., Dilek, S., 2005. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Human reproduction 20 5, 1207–12.
Feng, Y.Y., Wang, Z., Pang, H., 2023. Role of metformin in inflammation. Mol Biol Rep.
Fialoke, S., Malarstig, A., Miller, M.R., Dumitriu, A., 2018. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients. AMIA Annu Symp Proc 2018, 430–439.
Glueck, C.J., Moreira, A.C., Goldenberg, N., Sieve, L., Wang, P., 2003. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Human reproduction 18 8, 1618–25.
Gong, L., Goswami, S., Giacomini, K.M., Altman, R.B., Klein, T.E., 2012. Metformin pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22, 820–827.
Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J., Furlong, T.J., Greenfield, J.R., Greenup, L.C., Kirkpatrick, C.M., Ray, J.E., Timmins, P., Williams, K.M., 2011. Clinical Pharmacokinetics of Metformin. Clin Pharmacokinet 50, 81–98.
Hamudin A, Atik N. Mechanism of action of metformin as an anti-aging agent: a literature review. Intisari Sains Medis 2021;12:453–8. https://doi.org/10.15562/ism.v12i2.1058.
He, Z., Zhang, C., Liang, J.-X., Zheng, F.-F., Qi, X.-Y., Gao, F., 2023. Targeting Mitochondrial Oxidative Stress: Potential Neuroprotective Therapy for Spinal Cord Injury. J Integr Neurosci 22, 153. https://doi.org/10.31083/j.jin2206153
Hernández-Jiménez, J.L., Barrera, D., Espinoza-Simón, E., González, J., Ortíz-Hernández, R., Escobar, L., Echeverría, O., Torres-Ramírez, N., 2022. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. Gynecol Endocrinol 38, 2–9. https://doi.org/10.1080/09513590.2021.2003326
Hsu, S.-K., Cheng, K.-C., Mgbeahuruike, M.O., Lin, Y.-H., Wu, C.-Y., Wang, H.-M.D., Yen, C.-H., Chiu, C.-C., Sheu, S.-J., 2021. New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. Int J Mol Sci 22, 9453. https://doi.org/10.3390/ijms22179453
Huang KH, Chang YL, Gau SY, Tsai TH, Lee CY. Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus. Pharmaceutics 2022;14:1–14. https://doi.org/10.3390/pharmaceutics14050946.
Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP. Metformin inhibits TNF-α-induced IκB kinase phosphorylation, IκB-α degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009;134:169–75. https://doi.org/10.1016/j.ijcard.2008.04.010.
Jennison, E., Patel, J., Scorletti, E., Byrne, C.D., 2019. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J 95, 314–322. https://doi.org/10.1136/postgradmedj-2018-136316
Jin, Y., Heo, K.-S., 2023. Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development. Korean J Physiol Pharmacol 27, 299–310. https://doi.org/10.4196/kjpp.2023.27.4.299
Kriplani, A., Agarwal, N., 2004. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med 49 5, 361–7.
Kristófi, R., Eriksson, J.W., 2021. Metformin as an anti-inflammatory agent: A short review. Journal of Endocrinology.
Kulkarni, A.S., Gubbi, S., Barzilai, N., 2020. Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab 32, 15–30. https://doi.org/10.1016/j.cmet.2020.04.001
Layacha, S.Y., Biswas, D.A., 2023. Women With Polycystic Ovary Syndrome: A Review of Susceptibility to Type 2 Diabetes. Cureus 15, e33390. https://doi.org/10.7759/cureus.33390
Li, Y., Gappy, S., Liu, X., Sassalos, T., Zhou, T., Hsu, A., Zhang, A., Edwards, P.A., Gao, H., Qiao, X., 2022. Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium. PLoS One 17, e0268451. https://doi.org/10.1371/journal.pone.0268451
Lu M, Chen H, Nie F, Wei X, Tao Z, Ma J. The potential role of metformin in the treatment of Parkinson’s disease. J Bio-X Res2020;3:27–35. https://doi.org/10.1097/JBR.0000000000000055.
Lu, L.-J., Zhang, J., Jiang, Y., Han, Y.-H., Zhang, Y.-H., 2024. [Mechanism of mitochondrial dysfunction in polycystic ovary syndrome and traditional Chinese medicine intervention: a review]. Zhongguo Zhong Yao Za Zhi 49, 1–14. https://doi.org/10.19540/j.cnki.cjcmm.20231018.601
Lu, Y., Yuan, T., Min, X., Yuan, Z., Cai, Z., 2021. AMPK: Potential Therapeutic Target for Vascular Calcification. Front Cardiovasc Med 8, 670222. https://doi.org/10.3389/fcvm.2021.670222
MacIel, G.A.R., Hayashida, S.A.Y., Da Costa, L.C.V., Marcondes, J.A.M., Da Fonseca, A.M., Soares, J.M., Baracat, E.C., 2011. Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome. European Journal of Obstetrics and Gynecology and Reproductive Biology 157, 180–184.
Maideen, N.M.P., Jumale, A., Balasubramaniam, R., 2017. Drug interactions of metformin involving drug transporter proteins. Adv Pharm Bull.
Malekpour, K., Hazrati, A., Soudi, S., Roshangar, L., Pourfathollah, A.A., Ahmadi, M., 2023. Combinational administration of mesenchymal stem cell-derived exosomes and metformin reduces inflammatory responses in an in vitro model of insulin resistance in HepG2 cells. Heliyon 9, e15489. https://doi.org/10.1016/j.heliyon.2023.e15489
Markowicz-Piasecka, M., Huttunen, K.M., Mateusiak, L., Mikiciuk-Olasik, E., Sikora, J., 2016. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr Pharm Des 23.
Matsui, S., Yasui, T., Kasai, K., Keyama, K., Kato, T., Uemura, H., Kuwahara, A., Matsuzaki, T., Irahara, M., 2016. Changes of liver enzymes and triglyceride during the menopausal transition in Japanese women. J Obstet Gynaecol 36, 806–811. https://doi.org/10.3109/01443615.2016.1154516
Mima Y, Kuwashiro T, Yasaka M, Tsurusaki Y, Nakamura A, Wakugawa Y, Okada Y. Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. J Stroke Cerebrovasc Dis 2016;25:436–46. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.10.016.
Mohd Sahardi, N.F.N., Makpol, S., 2023. Suppression of Inflamm-Aging by Moringa oleifera and Zingiber officinale Roscoe in the Prevention of Degenerative Diseases: A Review of Current Evidence. Molecules 28, 5867. https://doi.org/10.3390/molecules28155867
Notaro, A.L.G., Neto, F.T.L., 2022. The use of metformin in women with polycystic ovary syndrome: an updated review. J Assist Reprod Genet.
Novi, S., Vestuto, V., Campiglia, P., Tecce, N., Bertamino, A., Tecce, M.F., 2023. Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation. Nutrients 15, 2748. https://doi.org/10.3390/nu15122748
O’Neill, B.J., 2020. Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome. Curr Opin Endocrinol Diabetes Obes 27, 301–307. https://doi.org/10.1097/MED.0000000000000569
Pillai, A.A., Melo, L., Frishman, W.H., Aronow, W.S., 2024. The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity. Cardiol Rev. https://doi.org/10.1097/CRD.0000000000000832
Postler, T.S., Peng, V., Bhatt, D.M., Ghosh, S., 2021. Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism. Sci Rep 11.
Riazi, K., Raman, M., Taylor, L., Swain, M.G., Shaheen, A.A., 2019. Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer? Nutrients 11, 2878. https://doi.org/10.3390/nu11122878
Saad, Z.A., Khodeer, D.M., Zaitone, S.A., Ahmed, A.A.M., Moustafa, Y.M., 2020. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin. Life Sci 253, 117725. https://doi.org/10.1016/j.lfs.2020.117725
Seow, K.-M., Chang, Y.-W., Chen, K.-H., Juan, C.-C., Huang, C.-Y., Lin, L.-T., Tsui, K.-H., Chen, Y.-J., Lee, W.-L., Wang, P.-H., 2020. Molecular Mechanisms of Laparoscopic Ovarian Drilling and Its Therapeutic Effects in Polycystic Ovary Syndrome. Int J Mol Sci 21, 8147. https://doi.org/10.3390/ijms21218147
Shelley, K., Articolo, A., Luthra, R., Charlton, M., 2023. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC Gastroenterol 23, 160. https://doi.org/10.1186/s12876-023-02794-4
Shun yu F, thai hong C, Ting Chen W, Chan L, Chien NL. Metformin adherence and the risk of cardiovascular disease: a population-based cohort study. Vaccine against Arterioscler an Updat 2023;14:1–10. https://doi.org/10.1177/https.
Sommer, J., Ehnis, H., Seitz, T., Schneider, J., Wild, A.B., Moceri, S., Buechler, C., Bozec, A., Weber, G.F., Merkel, S., Beckervordersandforth, R., Steinkasserer, A., Schüle, R., Trebicka, J., Hartmann, A., Bosserhoff, A., von Hörsten, S., Dietrich, P., Hellerbrand, C., 2023. Four-and-a-Half LIM-Domain Protein 2 (FHL2) Induces Neuropeptide Y (NPY) in Macrophages in Visceral Adipose Tissue and Promotes Diet-Induced Obesity. Int J Mol Sci 24, 14943. https://doi.org/10.3390/ijms241914943
Sugiarto, Diding HP, Guntur H, Marsetio D, Tjokroprawiro A. Peran Metformin terhadap Dislipidemia Aterogenik pada Sindroma Metabolik dengan Diabetes Mellitus Tipe-2 yang terawat jelek. J Kedokt Yars 2009;17:169–83.
Sunjaya, A.P., Sunjaya, A.F., 2021. Targeting ageing and preventing organ degeneration with metformin. Diabetes Metab 47, 101203. https://doi.org/10.1016/j.diabet.2020.09.009
Szczepańska, E., Gietka-Czernel, M., 2022. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res 54, 203–211. https://doi.org/10.1055/a-1778-4159
Tang, T., Glanville, J., Hayden, C.J., White, D.M., Barth, J.H., Balen, A.H., 2006. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human reproduction 21 1, 80–9.
the_efficacy_of_metformin_and_clomiphene_citrate.4-1, n.d.
U, S., S, S., R, D., 2019. Combined Clomiphene Citrate-Metformin Versus Letrozole-Metformin in Achieving Pregnancy among Women with Polycystic Ovary Syndrome. Gynecol Reprod Health 3.
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., Vancurova, I., 2018. Metformin as an Anticancer Agent. Trends Pharmacol Sci.
Vazirian, M., Nabavi, S.M., Jafari, S., Manayi, A., 2018. Natural activators of adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK) and their pharmacological activities. Food Chem Toxicol 122, 69–79. https://doi.org/10.1016/j.fct.2018.09.079
Wang, L., Pan, F., Luo, T., 2021. Sinapic Acid Attenuates Rheumatoid Arthritis Through Reducing Inflammation and Oxidative Stress by Downregulating IκB Kinase. J Interferon Cytokine Res 41, 347–354. https://doi.org/10.1089/jir.2021.0044
Ward, R.J., Dexter, D.T., Crichton, R.R., 2015. Ageing, neuroinflammation and neurodegeneration. Front Biosci (Schol Ed) 7, 189–204. https://doi.org/10.2741/S433
Wever, M.C.M., van Meer, F., Charbonnier, L., Crabtree, D.R., Buosi, W., Giannopoulou, A., Androutsos, O., Johnstone, A.M., Manios, Y., Meek, C.L., Holst, J.J., Smeets, P.A.M., Full4Health consortium, 2021. Associations between ghrelin and leptin and neural food cue reactivity in a fasted and sated state. Neuroimage 240, 118374. https://doi.org/10.1016/j.neuroimage.2021.118374
Whalen, K., 2018. Lippincott® illustrated reviews: pharmacology. Wolters kluwer india Pvt Ltd.
Wu, T., Xie, C., Wu, H., Jones, K.L., Horowitz, M., Rayner, C.K., 2017. Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes Obes Metab 19, 290–293.
Yang, J., Chen, C., 2024. Hormonal changes in PCOS. J Endocrinol 261, e230342. https://doi.org/10.1530/JOE-23-0342
Zain, M.M., Jamaluddin, R., Ibrahim, A., Norman, R.J., 2009. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 91, 514–521.
Zhu, Y.-X., Hu, H.-Q., Zuo, M.-L., Mao, L., Song, G.-L., Li, T.-M., Dong, L.-C., Yang, Z.-B., Ali Sheikh, M.S., 2021. Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation. Biomed Rep 15, 56. https://doi.org/10.3892/br.2021.1432


Komentar

Tulis Komentar

Komentar akan ditampilkan setelah disetujui admin

Belum ada komentar

Jadilah yang pertama berkomentar!